- Home
- ETON vs KURA Comparison
ETON vs KURA Comparison
Compare ETON & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ETON | KURA |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.7M | 841.6M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ETON | KURA |
|---|---|---|
| Price | $28.42 | $8.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $39.33 | $25.56 |
| AVG Volume (30 Days) | 380.3K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $79,950,000.00 | $67,482,000.00 |
| Revenue This Year | $40.90 | $28.28 |
| Revenue Next Year | $47.23 | $106.37 |
| P/E Ratio | $552.20 | ★ N/A |
| Revenue Growth | ★ 104.94 | 25.24 |
| 52 Week Low | $13.09 | $5.45 |
| 52 Week High | $35.66 | $12.49 |
Technical Indicators
Market Signals| Indicator | ETON | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 42.77 |
| Support Level | $28.00 | $8.80 |
| Resistance Level | $32.31 | $10.16 |
| Average True Range (ATR) | 1.96 | 0.63 |
| MACD | -0.80 | -0.19 |
| Stochastic Oscillator | 19.55 | 7.27 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.